Annual Securities Report — FY2025
What TAKARA HOLDINGS INC. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-25View the original on EDINET
How much it says
69Detailed
What moved here
25named for the first time
Its own wording
62terms
Which filing this is
32/ 32newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
In the fiscal year, revenue was ¥394,316 million, while operating profit of ¥17,076 million and net income attributable to owners of the parent of ¥11,696 million both declined year on year. Major changes included expenses related to TAKARA BIO INC.'s acquisition of Curio Bioscience, impairment losses, and shareholder returns through share buybacks and dividends under the dividend policy.
Komori's summary of this document, not the document's own words.69Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
77
Very detailed
97
Very detailed
62
Detailed
0
Almost nothing
50
Typical
68
Detailed
77
Very detailed
100
Very detailed
60
Detailed
79
Very detailed
73
Detailed
R&D spend72億円Money spent making new things.
Cash left over-72億円Cash from the business, less what went into equipment.
Spent on equipment245億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.